Apitope Announces Positive Results with Novel Treatment for Graves’ Disease

HASSELT, Belgium and CHEPSTOW, WalesApril 16, 2018 /PRNewswire/ —

Phase I data show early efficacy in the majority of patients and a very favourable safety profile

Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases (including multiple sclerosis (MS), Graves’ disease and uveitis), today announced positive results from the Phase I first in man clinical trial of its product candidate, ATX-GD-59, in development for the treatment of Graves’ disease.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH